SEC Form 4 · accession 0001415889-17-001499
MABVAX THERAPEUTICS HOLDINGS, INC. · MBVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John David Hansen
Officer — PRESIDENT AND CEO · Director
Period of report
Sep 15, 2017
Accepted (ET)
Sep 18, 2017 · 5:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001109196
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1 | — | Sep 15, 2017 | A | 176,054 | A | — | — | Common Stock | 176,054 | 176,054 | D |
Explanation of responses
- F1Grants of restricted stock units convert on a one-for-one basis into common stock and vest on January 8, 2018 or earlier under provisions of the Company's current equity incentive plan and individual employment agreements. Grants to management and board of directors are intended to provide incentives to remain at the company during activities related to evaluation of strategic options with an investment advisory bank intended on improving shareholder value and in consideration for potential success resulting from those efforts.